Find a Study

Change text size + -
 

RAD 2401

Principal Investigator(s):Bhargav Mistry M.D.
Condition:Renal Transplant Recipient
Specialty:Nephrology
Short Title:RAD 2401
Sponsor:Novartis
National Study ID:CRAD001 A 2401
Status:Open
Description:This is a multicenter, randomized, open-label, non-inferiority study.
Purpose:The purpose of this study is to examine the impact of Certican with reduced Neoral dose on efficacy failure and renal function relative to Myfortic with standard dose of Neoral.
Phase:III
Key Inclusion Criteria:
Patients currently enrolled in an everolimus (RAD) trial sponsored by Novartis. Patients currently on everolimus therapy. Adult or pediatric recipients of a solid organ transplant.
Key Exclusion Criteria:
Patients who are recipients of multiple solid organ transplants.
Contact:Vicki Oberg
Transplant Research Coordinator
234-6722
Vicki.Oberg@MeritCare.com
Last updated:Monday, March 17, 2008

 Return to Research Results

Research

For over two decades, Sanford Health has been a leader in clinical research. Visit our online guide to learn more about our current research and clinical trials.

Quality

Every day, Sanford Health is committed to quality health care and continuous improvements. Learn more in our online quality guide.